What topics does this cannabis study cover?

This study covers research on: Addiction, Neuroprotection.

Where was this research published?

Published in Journal of forensic and legal medicine on April 17, 2026.

Addiction Neuroprotection

Fatal drug combinations reveal dangers of polydrug use with cannabis

The Delhi Cocktail and the crisis of substance use: An autopsy-based pilot study.

Journal of forensic and legal medicine • April 17, 2026 • Moderately Relevant

🤖

AI Summary

This autopsy-based study examined fatal polydrug overdose cases in New Delhi, revealing a dangerous pattern of drug combinations the researchers termed the "Delhi Cocktail." The pattern involves three or more drugs, including at least one controlled substance alongside prescription medications—often including opioids, benzodiazepines, and other CNS depressants. The analysis included six fatal cases where tetrahydrocannabinol (THC) was identified alongside opioids, benzodiazepines, tricyclic antidepressants, and other substances, highlighting how cannabis consumption combined with other drugs dramatically increases overdose risk.

The most concerning finding was the co-use of prescription opioid treatments (methadone and buprenorphine) with street opioids, suggesting either non-compliance with addiction treatment protocols or unregulated drug access. When multiple CNS depressants are combined—particularly opioids with benzodiazepines, alcohol, or other drugs—the risk of fatal respiratory depression increases exponentially. Additional substances like tricyclic antidepressants and PCP further elevated risks by causing dangerous arrhythmia and neurotoxicity.

This study has important implications for cannabis users, particularly those taking opioid medications or benzodiazepines. The research underscores that cannabis should not be casually combined with other CNS depressants, as polydrug interactions can prove fatal. The researchers call for robust prescription monitoring systems, improved addiction treatment compliance programs, and enhanced forensic capabilities to identify emerging drug use patterns and prevent future overdose deaths.

📄 Original Abstract

This pilot study was conducted to analyze and describe recurring patterns of fatal polydrug use in autopsy cases. We also propose a novel descriptive term, "Delhi Cocktail," based on the specific pattern of drug use observed, and highlight the public health and medicolegal implications of such trends. This was an autopsy-based pilot study presenting six fatal instances of polydrug overdose in New Delhi. Each case involved the postmortem identification of distinct combinations of psychoactive substances, including illicit drugs and prescription medications. The "Delhi Cocktail" was defined by the postmortem presence of (1) three or more drugs, (2) at least one DEA Schedule I/II substance, and (3) a therapeutic drug used in addiction treatment or a psychotropic drug not prescribed to the individual. The substances most frequently identified in these fatal cases included opioids (morphine, methadone, buprenorphine, and tramadol), benzodiazepines, tricyclic antidepressants (TCAs), tetrahydrocannabinol (THC), and Phencyclidine (PCP). The misuse of opioid agonist therapies (methadone and buprenorphine) alongside street opioids suggested non-compliance with treatment or unregulated drug availability. The concurrent presence of multiple CNS depressants magnified the risk of fatal respiratory depression, while additives like TCAs and PCP increased the risk of arrhythmia and neurotoxicity. This pilot study, despite the lack of quantitative toxicological data, suggests the need for robust prescription monitoring systems, enhanced forensic infrastructure, and deaddiction protocols specifically tailored to address emerging trends in drug use.

Paper Type

📄 Research

Publication

Journal: Journal of forensic and legal medicine
Published: April 17, 2026
PMID: 42019361
DOI: 10.1016/j.jflm.2026.103135

Authors (5)

Aayushman Bherwal Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: aayushmaanbherwal66@gmail.com.
G Gokul Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: drgokug@gmail.com.
Manisha Thakur Department of Pharmaceutics (M. Pharma.), Bahra University, Shimla Hills, Himachal Pradesh, India. Electronic address: tmanisha410@gmail.com.
Taher Hussain Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: hussain01022000@gmail.com.
Sudhir K Gupta Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: sgupta52001@gmail.com.